New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract

Autoimmunity Reviews

Volumn 14, Issue 12, 2015, Pages 1161-1169

  Di Sabatino, Antonio ^a   Lenti, Marco Vincenzo ^a   Giuffrida, Paolo ^a   Vanoli, Alessandro ^a   Corazza, Gino Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autoimmune atrophic gastritis; Autoimmune enteropathy; Celiac disease; Cytokine; Ulcerative colitis

Indexed keywords

ANRUKINZUMAB; ANTIBODY; CYANOCOBALAMIN; ELDELUMAB; ENTEROCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; STEROID; TRALOKINUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; AUTOANTIBODY; CYTOKINE;

ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE ENTEROPATHY; CELIAC DISEASE; CELL FUNCTION; ENTEROPATHY; GASTRITIS; GASTROINTESTINAL TRACT; HUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; STOMACH ADENOCARCINOMA; STOMACH ATROPHY; STOMACH PARIETAL CELL; TH1 CELL; TH17 CELL; TISSUE INJURY; ULCERATIVE COLITIS; ANIMAL; GASTROINTESTINAL DISEASE; IMMUNOLOGY; INTESTINE CELL;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYTOKINES; ENTEROCYTES; GASTROINTESTINAL DISEASES; HUMANS;

EID: 84945461579     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.08.004     Document Type: Review

References (151)

1. Zhernakova A., van Diemen C.C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009, 10:43-55.
2. Selmi C. Hot topics in autoimmune diseases: perspectives from the 2013 Asian Congress of Autoimmunity. Autoimmun Rev 2014, 13:781-787.
3. Abu-Shakra M., Buskila D., Ehrenfeld M., Conrad K., Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001, 60:433-441.
4. Thewissen M., Stinissen P. New concepts on the pathogenesis of autoimmune diseases: a role for immune homeostasis, immunoregulation, and immunosenescence. Crit Rev Immunol 2008, 28:363-376.
5. Cope A.P., Feldmann M. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol 2004, 16:780-786.
6. Chatenoud L. Immune therapies of autoimmune diseases: are we approaching a real cure?. Curr Opin Immunol 2006, 18:710-717.
7. MacDonald T.T., Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005, 307:1920-1925.
8. Corazza G.R., Biagi F., Volta U., Andreani M.L., De Franceschi L., Gasbarrini G. Autoimmune enteropathy and villous atrophy in adults. Lancet 1997, 350:106-109.
9. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med 1996, 156:1097-1100.
10. Miceli E., Lenti M.V., Padula D., Luinetti O., Vattiato C., Monti C.M., et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol 2012, 10:812-814.
11. Di Sabatino A., Corazza G.R. Coeliac disease. Lancet 2009, 373:1480-1493.
12. Rugge M., Fassan M., Pizzi M., Zorzetto V., Maddalo G., Realdon S., et al. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther 2012, 35:1460-1466.
13. Neumann W.L., Coss E., Rugge M., Genta R.M. Autoimmune atrophic gastritis - pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013, 10:529-541.
14. Vanoli A., La Rosa S., Luinetti O., Klersy C., Manca R., Alvisi C., et al. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions. Hum Pathol 2013, 44:1827-1837.
15. +-adenosine triphosphatase of the stomach. J Clin Invest 1988, 81:475-479.
16. +)-ATPase induces a reversible autoimmune gastritis. Immunology 1997, 92:91-98.
17. Alderuccio F., Sentry J.W., Marshall A.C., Biondo M., Toh B.H. Animal models of human disease: experimental autoimmune gastritis - a model for autoimmune gastritis and pernicious anemia. Clin Immunol 2002, 102:48-58.
18. Suri-Payer E., Amar A.Z., McHugh R., Natarajan K., Margulies D.H., Shevach E.M. Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells. Eur J Immunol 1999, 29:669-677.
19. Suri-Payer E., Kehn P.J., Cheever A.W., Shevach E.M. Pathogenesis of post-thymectomy autoimmune gastritis. Identification of anti-H/K adenosine triphosphatase-reactive T cells. J Immunol 1996, 157:1799-1805.
20. Martinelli T.M., van Driel I.R., Alderuccio F., Gleeson P.A., Toh B.H. Analysis of mononuclear cell infiltrate and cytokine production in murine autoimmune gastritis. Gastroenterology 1996, 110:1791-1802.
21. Nishiura H., Iwamoto S., Kido M., Aoki N., Maruoka R., Ikeda A., et al. Interleukin-21 and tumor necrosis factor-α are critical for the development of autoimmune gastritis in mice. J Gastroenterol Hepatol 2013, 28:982-991.
22. Fornasa G., Tsilingiri K., Caprioli F., Botti F., Mapelli M., Meller S., et al. Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. J Allergy Clin Immunol 2015, 136:413-422.
23. Nishiura H., Kido M., Aoki N., Iwamoto S., Maruoka R., Ikeda A., et al. Increased susceptibility to autoimmune gastritis in thymic stromal lymphopoietin receptor-deficient mice. J Immunol 2012, 188:190-197.
24. Tu E., Ang D.K., Bellingham S.A., Hogan T.V., Teng M.W., Smyth M.J., et al. Both IFN-γ and IL-17 are required for the development of severe autoimmune gastritis. Eur J Immunol 2012, 42:2574-2583.
25. D'Elios M.M., Bergman M.P., Azzurri A., Amedei A., Benagiano M., De Pont J.J., et al. H(+), K(+)-atpase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology 2001, 120:377-386.
26. Valnes K., Huitfeldt H.S., Brandtzaeg P. Relation between T cell number and epithelial HLA class II expression quantified by image analysis in normal and inflamed human gastric mucosa. Gut 1990, 31:647-652.
27. Barrera C., Ye G., Espejo R., Gunasena S., Almanza R., Leary J., et al. Expression of cathepsins B, L, S, and D by gastric epithelial cells implicates them as antigen presenting cells in local immune responses. Hum Immunol 2001, 62:1081-1091.
28. Marshall A.C., Alderuccio F., Toh B.H. Fas/CD95 is required for gastric mucosal damage in autoimmune gastritis. Gastroenterology 2002, 123:780-789.
29. Judd L.M., Gleeson P.A., Toh B.H., van Driel I.R. Autoimmune gastritis results in disruption of gastric epithelial cell development. Am J Physiol 1999, 277:G209-G218.
30. Bedeir A.S., Lash R.H., Lash J.G., Ray M.B. Significant increase in IgG4+ plasma cells in gastric biopsy specimens from patients with pernicious anaemia. J Clin Pathol 2010, 63:999-1001.
31. Faller G., Kirchner T. Role of antigastric autoantibodies in chronic Helicobacter pylori infection. Microsc Res Tech 2000, 48:321-326.
32. Negrini R., Savio A., Poiesi C., Appelmelk B.J., Buffoli F., Paterlini A., et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996, 111:655-665.
33. D'Elios M.M., Appelmelk B.J., Amedei A., Bergman M.P., Del Prete G. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004, 10:316-323.
34. Brinton L.A., Gridley G., Hrubec Z., Hoover R., Fraumeni J.F. Cancer risk following pernicious anaemia. Br J Cancer 1989, 59:810-813.
35. Hsing A.W., Hansson L.E., McLaughlin J.K., Nyren O., Blot W.J., Ekbom A., et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993, 71:745-750.
36. Solcia E., Rindi G., Fiocca R., Villani L., Buffa R., Ambrosiani L., et al. Distinct patterns of chronic gastritis associated with carcinoid and cancer and their role in tumorigenesis. Yale J Biol Med 1992, 65:793-804.
37. Lahner E., Esposito G., Pilozzi E., Purchiaroni F., Corleto V.D., Di Giulio E., et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol 2015, 50:856-865.
38. Murphy G., Dawsey S.M., Engels E.A., Ricker W., Parsons R., Etemadi A., et al. Cancer risk after pernicious anemia in the US elderly population. Clin Gastroenterol Hepatol 2015, http://dx.doi.org/10.1016/j.cgh.2015.05.040, [Epub ahead of print].
39. Thompson P.A., Khatami M., Baglole C.J., Sun J., Harris S., Moon E.Y., et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis 2015, 36:S232-S253.
40. Gao L., Weck M.N., Nieters A., Brenner H. Association between a pro-inflammatory genetic profile and the risk of chronic atrophic gastritis among older adults from Germany. Eur J Cancer 2009, 45:428-434.
41. Figueiredo C.A., Marques C.R., Costa Rdos S., da Silva H.B., Alcantara-Neves N.M. Cytokines, cytokine gene polymorphisms and Helicobacter pylori infection: friend or foe?. World J Gastroenterol 2014, 20:5235-5243.
42. + T cells promotes the development of gastric cancer. Cancer Res 2013, 73:2117-2126.
43. Hakanson R., Sundler F. Trophic effects of gastrin. Scand J Gastroenterol Suppl 1991, 180:130-136.
44. Haley K.J., Patidar K., Zhang F., Emanuel R.L., Sunday M.E. Tumor necrosis factor induces neuroendocrine differentiation in small cell lung cancer cell lines. Am J Physiol 1998, 275:L311-L321.
45. Sollid L.M., Qiao S.W., Anderson R.P., Gianfrani C., Koning F. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 2012, 64:455-460.
46. Dubois P.C., Trynka G., Franke L., Hunt K.A., Romanos J., Curtotti A., et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010, 42:295-302.
47. van Heel D.A., Franke L., Hunt K.A., Gwilliam R., Zhernakova A., Inouye M., et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007, 39:827-829.
48. Heyman M., Abed J., Lebreton C., Cerf-Bensussan N. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut 2012, 61:1355-1364.
49. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity and cancer. Physiol Rev 2011, 91:151-175.
50. Matysiak-Budnik T., Cruz Moura I., Arcos-Fajardo M., Lebreton C., Ménard S., Tamouza H., et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008, 205:143-154.
51. Di Sabatino A., Vanoli A., Giuffrida P., Luinetti O., Solcia E., Corazza G.R. The function of tissue transglutaminase in celiac disease. Autoimmun Rev 2012, 11:746-753.
52. Lebreton C., Ménard S., Abed J., Cruz Moura I., Coppo R., Dugave C., et al. Interactions among secretory immunoglobulin A, CD71, and Transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 2012, 143:698-707.
53. Biancheri P., Di Sabatino A., Rescigno M., Giuffrida P., Fornasa G., Tsilingiri K., et al. Abnormal thymic stromal lymphopoietin expression in the duodenal mucosa of patients with coeliac disease. Gut 2015, [in press].
54. Monteleone I., Monteleone G., Del Vecchio Blanco G., Vavassori P., Cucchiara S., MacDonald T.T., et al. Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa. Gut 2004, 53:1090-1095.
55. Monteleone I., Sarra M., Del Vecchio Blanco G., Paoluzi O.A., Franzè E., Fina D., et al. Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol 2010, 184:2211-2218.
56. Fina D., Sarra M., Caruso R., Del Vecchio Blanco G., Pallone F., MacDonald T.T., et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 2008, 57:887-892.
57. Di Niro R., Mesin L., Zheng N.Y., Stamnaes J., Morrissey M., Lee J.H., et al. High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat Med 2012, 18:441-445.
58. Iversen R., Mysling S., Hnida K., Jørgensen T.J., Sollid L.M. Activity-regulating structural changes and autoantibody epitopes in transglutaminase 2 assessed by hydrogen/deuterium exchange. Proc Natl Acad Sci U S A 2014, 111:17146-17151.
59. Di Sabatino A., Calarota S.A., Vidali F., MacDonald T.T., Corazza G.R. Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev 2011, 22:19-33.
60. Di Sabatino A., Ciccocioppo R., Cupelli F., Cinque B., Millimaggi D., Clarkson M.M., et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 2006, 55:469-477.
61. Jabri B., de Serre N.P., Cellier C., Evans K., Gache C., Carvalho C., et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000, 118:867-879.
62. Sarra M., Cupi M.L., Monteleone I., Franzè E., Ronchetti G., Di Sabatino A., et al. IL-15 positively regulates IL-21 production in celiac disease mucosa. Mucosal Immunol 2013, 6:244-255.
63. Belhadi Hmida N., Ben Ahmed M., Moussa A., Ben Rejeb M., Said Y., Kourda N., et al. Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease?. Am J Gastroenterol 2012, 107:604-611.
64. Benahmed M., Meresse B., Arnulf B., Barbe U., Mention J.J., Verkarre V., et al. Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology 2007, 132:994-1008.
65. Biancheri P., Giuffrida P., Docena G.H., MacDonald T.T., Corazza G.R., Di Sabatino A. The role of transforming growth factor (TGF)-β in modulating the immune response and fibrogenesis in the gut. Cytokine Growth Factor Rev 2014, 25:45-55.
66. Di Sabatino A., Biagi F., Gobbi P.G., Corazza G.R. How I treat enteropathy-associated T-cell lymphoma. Blood 2012, 119:2458-2468.
67. Caruso R., Marafini I., Sedda S., Del Vecchio Blanco G., Giuffrida P., MacDonald T.T., et al. Analysis of cytokine profile in the duodenal mucosa of refractory coeliac disease patients. Clin Sci (Lond) 2014, 126:451-458.
68. Veeraraghavan G., Leffler D.A., Kaswala D.H., Mukherjee R. Celiac disease 2015 update: new therapies. Expert Rev Gastroenterol Hepatol 2015, 9:913-927.
69. Leffler D.A., Kelly C.P., Green P.H., Fedorak R.N., DiMarino A., Perrow W., et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 2015, 148:1311-1319.
70. Lähdeaho M.L., Kaukinen K., Laurila K., Vuotikka P., Koivurova O.P., Kärjä-Lahdensuu T., et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014, 146:1649-1658.
71. Tack G.J., van de Water J.M., Bruins M.J., Kooy-Winkelaar E.M., van Bergen J., Bonnet P., et al. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J Gastroenterol 2013, 19:5837-5847.
72. Korponay-Szabo I., Tumpek J., Gyimesi J., Laurila K., Papp M., Maki M., et al. Food-grade degrading enzymes to treat dietary transgressions in coeliac adolescents. J Pediatric Gastroenterology Nutrition Hepatology and Nutrition Annual Meeting; Istambul, Turkey 2010, E68.
73. Lindfors K., Blomqvist T., Juuti-Uusitalo K., Stenman S., Venäläinen J., Mäki M., et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008, 152:552-558.
74. De Palma G., Cinova J., Stepankova R., Tuckova L., Sanz Y. Pivotal advance: Bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. J Leukoc Biol 2010, 87:765-778.
75. Pinier M., Verdu E.F., Nasser-Eddine M., David C.S., Vézina A., Rivard N., et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009, 136:288-298.
76. Brown G.J., Daveson J., Marjason J.K., Ffrench R.A., Smith D., Sullivan M., et al. A phase I study to determine safety, tolerability and bioactivity of Nexvax2® in HLA DQ2+ volunteers with celiac disease following a long-term, strict gluten-free diet. Gastroenterology 2011, 140:S437-S438.
77. A Phase II Study of CCX282-B in Patients With Celiac Disease Available from. https://clinicaltrials.gov/ct2/show/NCT00540657.
78. Siegel M., Xia J., Khosla C. Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg Med Chem 2007, 15:6253-6261.
79. Malamut G., El Machhour R., Montcuquet N., Martin-Lannerée S., Dusanter-Fourt I., Verkarre V., et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010, 120:2131-2143.
80. Antibody Treatment for Advanced Celiac Disease Available from. https://clinicaltrials.gov/ct2/show/NCT01893775?term=celiac+disease&rank=23.
81. Unsworth D.J., Walker-Smith J.A. Autoimmunity in diarrhoeal disease. J Pediatr Gastroenterol Nutr 1985, 4:375-380.
82. Akram S., Murray J.A., Pardi D.S., Alexander G.L., Schaffner J.A., Russo P.A., et al. Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clin Gastroenterol Hepatol 2007, 5:1282-1290.
83. Masia R., Peyton S., Lauwers G.Y., Brown I. Gastrointestinal biopsy findings of autoimmune enteropathy: a review of 25 cases. Am J Surg Pathol 2014, 38:1319-1329.
84. León F., Olivencia P., Rodríguez-Pena R., Sánchez L., Redondo C., Alvarez I., et al. Clinical and immunological features of adult-onset generalized autoimmune gut disorder. Am J Gastroenterol 2004, 99:1563-1571.
85. Montalto M., D'Onofrio F., Santoro L., Gallo A., Gasbarrini A., Gasbarrini G. Autoimmune enteropathy in children and adults. Scand J Gastroenterol 2009, 44:1029-1036.
86. Walker-Smith J.A., Unsworth D.J., Hutchins P., Phillips A.D., Holborow E.J. Autoantibodies against gut epithelium in a child with small intestinal enteropathy. Lancet 1982, 1:566-567.
87. Mirakian R., Hill S., Richardson A., Milla P.J., Walker-Smith J.A., Bottazzo G.F. HLA product expression and lymphocyte subpopulation in jejunum biopsies of children with idiopathic protracted diarrhoea and enterocyte autoantibodies. J Autoimmun 1988, 1:263-277.
88. Hill S., Milla P.J., Ciampolillo A., Napolitano G., Bottazzo G.F., Mirakian R. LFA-1 and ICAM-1 molecule expression in jejunal mucosa from children with autoimmune enteropathy. Autoimmunity 1992, 13:233-241.
89. Moore L., Xu X., Davidson G., Moore D., Carli M., Ferrante A. Autoimmune enteropathy with anti-goblet cell antibodies. Hum Pathol 1995, 26:1162-1168.
90. Lachaux A., Loras-Duclaux I., Bouvier R. Autoimmune enteropathy in infants: pathological study of the disease in two familial cases. Virchows Arch 1998, 433:481-485.
91. Ciccocioppo R., D'alò S., Di Sabatino A., Parroni R., Rossi M., Doglioni C., et al. Mechanisms of villous atrophy in autoimmune enteropathy and coeliac disease. Clin Exp Immunol 2002, 128:88-93.
92. Valitutti F., Barbato M., Aloi M., Marcheggiano A., Di Nardo G., Leoni S., et al. Autoimmune enteropathy in a 13-year-old celiac girl successfully treated with infliximab. J Clin Gastroenterol 2014, 48:264-266.
93. Elwing J.E., Clouse R.E. Adult-onset autoimmune enteropathy in the setting of thymoma successfully treated with infliximab. Dig Dis Sci 2005, 50:928-932.
94. von Hahn T., Stopik D., Koch M., Wiedenmann B., Dignass A. Management of severe refractory adult autoimmune enteropathy with infliximab and tacrolimus. Digestion 2005, 71:141-144.
95. Quiros B.A., Sanz A.E., Ordiz B.E., Garrote Adrados J.A. From autoimmune enteropathy to the IPEX (immune dysfunction, polyendocrinopathy, enteropathy, X-linked) syndrome. Allergol Immunopathol 2009, 37:208-215.
96. Kisand K., Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known novel aspects of the syndrome. Ann N Y Acad Sci 2011, 1246:77-91.
97. Gentile N.M., Murray J.A., Pardi D.S. Autoimmune enteropathy: a review and update of clinical management. Curr Gastroenterol Rep 2012, 14:380-385.
98. Sanderson I.R., Phillips A.S., Spencer J., Walker-Smith J.A. Response to autoimmune enteropathy to cyclosporin A therapy. Gut 1991, 32:1421-1425.
99. Bousvaros A., Leichtner A.M., Book L., Shigeoka A., Bilodeau J., Semeao E., et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology 1996, 111:237-243.
100. Malamut G., Verkarre V., Callens C., Colussi O., Rahmi G., MacIntyre E., et al. Enteropathy-associated T-cell lymphoma complicating an autoimmune enteropathy. Gastroenterology 2012, 142:726-729.
101. Di Sabatino A., Biancheri P., Rovedatti L., MacDonald T.T., Corazza G.R. Recent advances in understanding ulcerative colitis. Intern Emerg Med 2012, 7:103-111.
102. Geremia A., Biancheri P., Allan P., Corazza G.R., Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014, 13:3-10.
103. Biancheri P., Di Sabatino A., Corazza G.R., MacDonald T.T. Proteases and the gut barrier. Cell Tissue Res 2013, 351:269-280.
104. Sträter J., Wellisch I., Riedl S., Walczak H., Koretz K., Tandara A., et al. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997, 113:160-167.
105. Masuda H., Iwai S., Tanaka T., Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995, 46:111-123.
106. Bernardo D., Vallejo-Díez S., Mann E.R., Al-Hassi H.O., Martínez-Abad B., Montalvillo E., et al. IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and T cells they stimulate. Eur J Immunol 2012, 42:1337-1353.
107. Rovedatti L., Kudo T., Biancheri P., Sarra M., Knowles C.H., Rampton D.S., et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009, 58:1629-1636.
108. Pastorelli L., Garg R.R., Hoang S.B., Spina L., Mattioli B., Scarpa M., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 2010, 107:8017-8022.
109. Imaeda H., Takahashi K., Fujimoto T., Kasumi E., Ban H., Bamba S., et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 2013, 172:410-416.
110. Thomas S., Baumgart D.C. Targeting leucocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012, 20:1-18.
111. Pender S.L., MacDonald T.T. Matrix metalloproteinases and the gut - new roles for old enzymes. Curr Opin Pharmacol 2004, 4:546-550.
112. Di Sabatino A., Pender S.L., Jackson C.L., Prothero J.D., Gordon J.N., Picariello L., et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007, 133:137-149.
113. Gordon J.N., Pickard K.M., Di Sabatino A., Prothero J.D., Pender S.L., Goggin P.M., et al. Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:195-203.
114. Louis E., Ribbens C., Godon A., Franchimont D., De Groote D., Hardy N., et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000, 120:241-246.
115. Biancheri P., Brezski R.J., Di Sabatino A., Greenplate A.R., Soring K.L., Corazza G.R., et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology 2015, [Epub ahead of print]. 10.1053/j.gastro.2015.07.002.
116. Di Sabatino A., Pickard K.M., Rampton D., Kruidenier L., Rovedatti L., Leakey N.A., et al. Blockade of transforming growth factor beta upregulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut 2008, 57:605-612.
117. Monteleone G., Kumberova A., Croft N.M., McKenzie C., Steer H.W., MacDonald T.T. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001, 108:601-609.
118. Franzè E., Rizzo A., Caruso R., Pallone F., Monteleone G. Interleukin-25 negatively controls pathogenic responses in the gut. Inflamm Allergy Drug Targets 2011, 10:187-191.
119. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544.
120. 2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J Immunol 2009, 183:3454-3462.
121. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996, 157:1261-1270.
122. Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129:550-564.
123. Heller F., Fuss I.J., Nieuwenhuis E.E., Blumberg R.S., Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002, 17:629-638.
124. Biancheri P., Di Sabatino A., Ammoscato F., Facciotti F., Caprioli F., Curciarello R., et al. Absence of a role for interleukin-13 in inflammatory bowel disease. Eur J Immunol 2014, 44:370-385.
125. Danese S., Rudziński J., Brandt W., Dupas J.L., Peyrin-Biroulet L., Bouhnik Y., et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 2015, 64:243-249.
126. Reinisch W., Panés J., Khurana S., Toth G., Hua F., Comer G.M., et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut 2015, 64:894-900.
127. Samaan M.A., Bagi P., Vande Casteele N., D'Haens G.R., Levesque B.G. An update on anti-TNF agents in ulcerative colitis. Gastroenterol Clin North Am 2014, 43:479-494.
128. Sandborn W.J., Ghosh S., Panes J., Vranic I., Su C., Rousell S., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012, 367:616-624.
129. Briskin M., Winsor-Hines D., Shyjan A., Cochran N., Bloom S., Wilson J., et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated with lymphoid tissue. Am J Pathol 1997, 151:97-110.
130. Souza H.S., Elia C.C., Spencer J., MacDonald T.T. Expression of lymphocyte-endothelial receptor ligand pairs, α4β7/MAdCAM 1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999, 45:856-863.
131. Mosli M.H., MacDonald J.K., Bickston S.J., Behm B.W., Tsoulis D.J., Cheng J., et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis 2015, 21:1151-1159.
132. Vermeire S., O'Byrne S., Keir M., Williams M., Lu T.T., Mansfield J.C., et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014, 384:309-318.
133. Van Raemdonck K., Van den Steen P.E., Liekens S., Van Damme J., Struyf S. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev 2015, 26:311-327.
134. Uguccioni M., Gionchetti P., Robbiani D.F., Rizzello F., Peruzzo S., Campieri M., et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 1999, 155:331-336.
135. Mayer L., Sandborn W.J., Stepanov Y., Geboes K., Hardi R., Yellin M., et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 2014, 63:442-450.
136. Uchiyama K., Naito Y., Takagi T., Mizushima K., Hirai Y., Hayashi N., et al. Serpin B1 protects colonic epithelial cell via blockage of neutrophil elastase activity and its expression is enhanced in patients with ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2012, 302:G1163-G1170.
137. Giuffrida P., Biancheri P., MacDonald T.T. Proteases and small intestinal barrier function in health and disease. Curr Opin Gastroenterol 2014, 30:147-153.
138. Nalleweg N., Chiriac M.T., Podstawa E., Lehmann C., Rau T.T., Atreya R., et al. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut 2015, 64:743-755.
139. Speca S., Dubuquoy L., Desreumaux P. Peroxisome proliferator-activated receptor gamma in the colon: inflammation and innate antimicrobial immunity. J Clin Gastroenterol 2014, 48:23-27.
140. Lewis J.D., Lichtenstein G.R., Deren J.J., Sands B.E., Hanauer S.B., Katz J.A., et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008, 134:688-695.
141. Celinski K., Dworzanski T., Fornal R., Korolczuk A., Madro A., Brzozowski T., et al. Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis. J Physiol Pharmacol 2013, 64:587-595.
142. Herszényi L., Tulassay Z. The role of autoantibodies in inflammatory bowel disease. Dig Dis 2012, 30:201-207.
143. Ferrante M., Vermeire S., Katsanos K.H., Noman M., Van Assche G., Schnitzler F., et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007, 13:123-128.
144. Fleshner P.R., Vasiliauskas E.A., Kam L.Y., Fleshner N.E., Gaiennie J., Abreu-Martin M.T., et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001, 49:671-677.
145. Okayasu I. Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol Int 2012, 62:368-380.
146. Jess T., Rungoe C., Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012, 10:639-645.
147. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
148. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 transsignaling. Immunity 2004, 21:491-501.
149. Mitsuyama K., Sata M., Rose-John S. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev 2006, 17:451-461.
150. Yoshimura A., Mori H., Ohishi M., Aki D., Hanada T. Negative regulation of cytokine signaling influences inflammation. Curr Opin Immunol 2003, 15:704-708.
151. Li Y., de Haar C., Chen M., Deuring J., Gerrits M.M., Smits R., et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010, 59:227-235.